The Bone Marrow Comprehensive Report : Advances in Molecular and Cytogenetic Risk Stratification in AML and MDS

Because ancillary testing is necessary to supplement morphologic features in the diagnosis of most hematologic neoplasms, hematopathologists have traditionally consolidated a variety of information into diagnostic pathology reports. Initially, this information included clinical features of the patient, morphologic features and tests that represented cytochemical and immunophenotyping studies. Cytogenetic and molecular genetic studies, however, are increasingly important and necessary for complete diagnosis and for predicting prognosis in most hematologic neoplasms. The logistics of reporting all of this information, which includes tests that may be resulted at different times, is a challenge for all pathology specialties. The complexities of the information produced by next generation sequencing methods significantly increases this challenge for pathologists.

[1]  J. Vardiman,et al.  Acute Myeloid Leukemia With Myelodysplasia-Related Changes. , 2015, American journal of clinical pathology.

[2]  Tina Hambuch,et al.  Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. , 2012, The Journal of molecular diagnostics : JMD.

[3]  D. Arber,et al.  DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups , 2012, British journal of haematology.

[4]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[6]  Isaac S. Kohane,et al.  Technical desiderata for the integration of genomic data into Electronic Health Records , 2012, J. Biomed. Informatics.

[7]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[8]  S. Salzberg,et al.  Repetitive DNA and next-generation sequencing: computational challenges and solutions , 2011, Nature Reviews Genetics.

[9]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[10]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[11]  W. Grody,et al.  Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. , 2008, The Journal of molecular diagnostics : JMD.

[12]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[13]  M. Gulley,et al.  Clinical laboratory reports in molecular pathology. , 2007, Archives of pathology & laboratory medicine.

[14]  B. Nathwani,et al.  Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. The Ad Hoc Committee on reporting of lymphoid neoplasms. , 2002, Human pathology.

[15]  L. Peterson,et al.  Protocol for the examination of specimens from patients with hematopoietic neoplasms of the bone marrow: a basis for checklists. , 2002, Archives of pathology & laboratory medicine.

[16]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[17]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[18]  C. Bloomfield,et al.  The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .

[19]  S. Trent Rosenbloom,et al.  Quill: A Novel Approach to Structured Reporting , 2003, AMIA.

[20]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.